title: Steroidogenic capacity of residual ovarian tissue in 4-vinylcyclohexene diepoxide-treated mice.
abstract: Menopause is an important public health issue because of its association with a number of disorders. Androgens produced by residual ovarian tissue after menopause could impact the development of these disorders. It has been unclear, however, whether the postmenopausal ovary retains steroidogenic capacity. Thus, an ovary-intact mouse model for menopause that uses the occupational chemical 4-vinylcyclohexene diepoxide (VCD) was used to characterize the expression of steroidogenic genes in residual ovarian tissue of follicle-depleted mice. Female B6C3F1 mice (age, 28 days) were dosed daily for 20 days with either vehicle or VCD (160 mg kg(-1) day(-1)) to induce ovarian failure. Ovaries were collected on Day 181 and analyzed for mRNA and protein. Acyclic aged mice were used as controls for natural ovarian senescence. Relative to cycling controls, expression of mRNA encoding steroidogenic acute regulatory protein (Star); cholesterol side-chain cleavage (Cyp11a1); 3beta-hydroxysteroid dehydrogenase (Hsd3b); 17alpha-hydroxylase (Cyp17a1); scavenger receptor class B, type 1 (Scarb1); low-density lipoprotein receptor (Ldlr); and luteinizing hormone receptor (Lhcgr) was enriched in VCD-treated ovaries. In acyclic aged ovaries, mRNA expression for only Cyp17a1 and Lhcgr was greater than that in controls. Compared to cycling controls, ovaries from VCD-treated and aged mice had similar levels of HSD3B, CYP17A1, and LHCGR protein. The pattern of protein immunofluorescence staining for HSD3B in follicle-depleted (VCD-treated) ovaries was homogeneous, whereas that for CYP17A1 was only seen in residual interstitial cells. Circulating levels of FSH and LH were increased, and androstenedione levels were detectable following follicle depletion in VCD-treated mice. These findings support the idea that residual ovarian tissue in VCD-treated mice retains androgenic capacity.
authors.affiliation: Department of Physiology, University of Arizona, Tucson, Arizona 85724-5051, USA.
authors.forename: Zelieann
authors.initials: Z
authors.lastname: Rivera
authors.forename: Patricia J
authors.initials: PJ
authors.lastname: Christian
authors.forename: Sam L
authors.initials: SL
authors.lastname: Marion
authors.forename: Heddwen L
authors.initials: HL
authors.lastname: Brooks
authors.forename: Patricia B
authors.initials: PB
authors.lastname: Hoyer
mesh_terms: D000735:Androstenedione / Q000097:blood; D000818:Animals; D002273:Carcinogens; D053138:Cyclohexenes; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics / Q000378:metabolism; D030762:Estrous Cycle / Q000187:drug effects / Q000235:genetics / Q000502:physiology; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects; D012739:Gonadal Steroid Hormones / Q000096:biosynthesis*; D006913:Hydroxysteroid Dehydrogenases / Q000235:genetics / Q000378:metabolism; D007986:Luteinizing Hormone / Q000097:blood; D051379:Mice; D008810:Mice, Inbred C57BL; D010053:Ovary / Q000187:drug effects / Q000378:metabolism*; D016649:Primary Ovarian Insufficiency / Q000097:blood / Q000139:chemically induced* / Q000235:genetics / Q000378:metabolism*; D014753:Vinyl Compounds
chemical_list: D002273:Carcinogens; D053138:Cyclohexenes; D012739:Gonadal Steroid Hormones; D014753:Vinyl Compounds; D000735:Androstenedione; C012606:4-vinyl-1-cyclohexene dioxide; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D003577:Cytochrome P-450 Enzyme System; D006913:Hydroxysteroid Dehydrogenases